Clinical Trials Directory

Trials / Unknown

UnknownNCT03494738

Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

Status
Unknown
Phase
Study type
Observational
Enrollment
600 (actual)
Sponsor
CAMC Health System · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by PEth blood spot testing.

Detailed description

Fetal alcohol spectrum disorders (FASD) are a group of conditions that can occur in a person whose birth mother consumed alcohol during pregnancy. The effects can include physical problems and/or difficulties with behavior and learning. When clinicians identify FASD early, intervention approaches can minimize the potential impact and lessen or even prevent disabilities. Thus, objective markers for prenatal alcohol exposure are desired. Using dried blood spots from the umbilical cord and a heel stick of newborns, this study will use Phosphatidylethanol (PEth), a novel biomarker for alcohol exposure, to identify and characterize infants' exposure to alcohol before birth. Additionally, the dried blood spots will used to validate the use of screening assays using epigenetic changes as markers for prenatal alcohol exposure. Epigenetic changes are heritable changes in DNA that affect DNA function but do not change DNA sequence. The use of PEth testing will allow for the correlation of prenatal alcohol exposure levels with epigenetic changes. Women will be consented prior to delivery for participation in this prospective study. The study will be conducted in collaboration with United States Drug Testing Laboratories, Inc. (USDTL).

Conditions

Timeline

Start date
2018-04-12
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2018-04-11
Last updated
2022-09-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03494738. Inclusion in this directory is not an endorsement.